Relay Therapeutics (NASDAQ:RLAY) Stock: Insider Sanjiv Patel Sells 48,202 Shares

Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) CEO Sanjiv Patel sold 48,202 shares of the stock in a transaction dated Thursday, November 19th. The stock was sold at an average price of $16.13, for a total transaction of $777,498.26. Following the completion of the transaction, the chief executive officer owned 423,099 shares of the company’s stock, valued at approximately $6,824,586.87. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Sanjiv Patel also recently made the following trade(s):

  • On Wednesday, October 7th, Sanjiv Patel sold 48,199 shares of Relay Therapeutics stock. The shares were sold at an average price of $18.10, for a total transaction of $872,401.90.
  • On Tuesday, September 8th, Sanjiv Patel sold 48,199 shares of Relay Therapeutics stock. The shares were sold at an average price of $18.94, for a total value of $912,889.06.

Relay Therapeutics Stock Up 1.3%

Shares of RLAY opened at $16.11 on Friday. Relay Therapeutics, Inc. has a 52 week low of $6.28 and a 52 week high of $21.27. The business has a 50-day simple moving average of $18.13 and a two-hundred day simple moving average of $15.70. The stock has a market cap of $3.56 billion, a price-to-earnings ratio of -10.67 and a beta of 1.74.

Relay Therapeutics (NASDAQ:RLAY – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.03. On average, equities analysts anticipate that Relay Therapeutics, Inc. will post -1.58 earnings per share for the current fiscal year.

Institutional Trading of Relay Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Relay Therapeutics during the second quarter worth $286,042,000. Perceptive Advisors LLC increased its position in shares of Relay Therapeutics by 412.3% during the first quarter. Perceptive Advisors LLC now owns 9,751,141 shares of the company’s stock valued at $97,024,000 after buying an additional 7,847,896 shares during the period. Spruce Street Capital LP purchased a new position in Relay Therapeutics during the second quarter worth about $55,832,979. Bank of America Corp DE purchased a new position in Relay Therapeutics in the 2nd quarter worth approximately $50,425,000. Finally, Dimensional Fund Advisors LP lifted its stake in Relay Therapeutics by 18.6% during the first quarter. Dimensional Fund Advisors LP now owns 2,940,536 shares of the company’s stock worth $29,248,000 after purchasing an additional 460,186 shares during the last quarter. Institutional investors own 96.98% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. JonesTrading raised their target price on Relay Therapeutics from $20.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relay Therapeutics in a report on Friday, October 2nd. Citizens Jmp upped their target price on Relay Therapeutics from $21.00 to $26.00 and gave the stock a “market outperform” rating in a research report on Monday, August 10th. Zacks Research raised shares of Relay Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. Finally, HC Wainwright boosted their target price on shares of Relay Therapeutics from $28.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Relay Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $27.00.

Get Our Latest Stock Analysis on RLAY

About Relay Therapeutics

(Get Free Report)

Relay Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines for patients with serious diseases, with an emphasis on cancer. The company uses its computational drug discovery platform to study how proteins move and interact, aiming to identify drug targets and design therapies against them. Relay’s research combines experimental biology, structural biology and computational methods. Its drug development programs have included candidates targeting cancer-related pathways, such as FGFR2 and PI3Kα.

Featured Stories

Insider Buying and Selling by Quarter for Relay Therapeutics (NASDAQ:RLAY)

Receive News & Ratings for Relay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.